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Abstract
Background: Multiple Myeloma (MM) is a B-cell malignancy in which clonal plasma cells progressively expand
within the bone marrow (BM) as effect of complex interactions with extracellular matrix and a number of
microenvironmental cells. Among these, cancer-associated fibroblasts (CAF) mediate crucial reciprocal signals
with MM cells and are associated to aggressive disease and poor prognosis. A large body of evidence emphasizes the
role of the urokinase plasminogen activator (u-PA) and its receptor u-PAR in potentiating the invasion capacity of
tumor plasma cells, but little is known about their role in the biology of MM CAF. In this study, we investigated the
u-PA/u-PAR axis in MM-associated fibroblasts and explore additional mechanisms of tumor/stroma interplay in MM
progression.
Methods: CAF were purified from total BM stromal fraction of 64 patients including monoclonal gammopathy of
undetermined significance, asymptomatic and symptomatic MM, as well as MM in post-treatment remission. Flow
cytometry, Real Time PCR and immunofluorescence were performed to investigate the u-PA/u-PAR system in relation
to the level of activation of CAF at different stages of the disease. Moreover, proliferation and invasion assays coupled
with silencing experiments were used to prove, at functional level, the function of u-PAR in CAF.
Results: We found higher activation level, along with increased expression of pro-invasive molecules, including u-PA,
u-PAR and metalloproteinases, in CAF from patients with symptomatic MM compared to the others stages of the
disease. Consistently, CAF from active MM as well as U266 cell line under the influence of medium conditioned by
active MM CAF, display higher proliferative rate and invasion potential, which were significantly restrained by u-PAR
gene expression inhibition.
Conclusions: Our data suggest that the stimulation of u-PA/u-PAR system contributes to the activated phenotype and
function of CAF during MM progression, providing a biological rationale for future targeted therapies against MM.
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Background
Multiple myeloma (MM) is an incurable haematological
malignancy in which plasma cells (PC) progressively ex-
pand as effect of sequential genetic changes and multiple
interactions with bone marrow (BM) microenvironment
[1]. The common clinical evolution from monoclonal
gammopathy of undetermined significance (MGUS)
toward asymptomatic and symptomatic active MM is
underlain by a multistep process in which both plasma
cells and their local microenvironment undergo progres-
sive changes that, in turn, foster growth and survival of
transformed cells [2]. Fibroblasts are a prominent cellu-
lar component of BM microenvironment and, under the
influence of tumor and inflammatory factors, acquire a
persistent state of activation, which is typical of the
cancer-associated fibroblasts (CAF) [3]. CAF typically
display enhanced expression of structural proteins as
alpha-smooth muscle actin (α-SMA), vimentin and
fibroblast specific protein 1 (FSP-1), and secrete high
amounts of cytokines and growth factors directly in-
volved in MM pathogenesis, such as interleukin 6 (IL-6),
vascular endothelial growth factor (VEGF), transforming
growth factor-beta (TGF-β), fibroblast growth factor-2
(FGF-2), and hepatocyte growth factor (HGF). They also
gain improved capacity of extracellular matrix (ECM)
degradation by over-producing metalloproteinases (MMPs)
and other enzymes [4], which favours the expansion of PC
clone within the BM [5].
Conversion of plasminogen into the broad-spectrum
protease plasmin is known to contribute to ECM deg-
radation in both solid and hematologic tumors such as
MM [6–8]. This process, in turn, depends on the activa-
tion of the urokinase-type plasminogen activator (u-PA)
system, which is composed by the proteinase u-PA, its
receptor u-PAR and two major plasminogen activation
inhibitors (PAI-1 and -2) [9]. The u-PA system mediates
cell invasion [10, 11], the MMP-dependent BM degrad-
ation [12, 13], and stimulates the production of MM-
supporting factors, such as HGF, by BM stromal cells
[14]. Increasing evidence suggests a critical relation
between u-PA system activation and MM aggressiveness
and high levels of soluble u-PAR were described as an
independent negative prognostic factor in MM [15, 16].
However, despite most research focused on the role of
this system in cancer cells, very little is known about its
function in CAF as pivotal controllers of MM progression.
We hypothesized that the activation state of CAF in
MM may also involve a peculiar modulation of the u-
PAR-controlled proteolytic activity of these cells. Thus,
we explored the grade of functional activation of CAF
from different clinical phases of the disease, in relation
to both expression and function of major uPA system
components. Intriguingly, we observed that CAF from
patients with active disease show a significant up-regulation
of the fibrinolytic system, prompt U-266 cell line invasivity
and exert themselves higher proliferative and invasion cap-
acity, which are dramatically restrained by a selective
u-PAR silencing.
Methods
Patients and cell cultures
BM aspirates were obtained for diagnostic purpose from
64 subjects including 18 MGUS, 14 asymptomatic MM
(aMM), 20 symptomatic active MM (sMM), and 12 MM
in remission phase (rMM). sMM patients had a median
age of 72 years, they were newly diagnosed and
treatment-naïve. The median age was 75 years for both
MGUS and aMM groups, whereas rMM patients had a
median age of 79 years and were all in complete remis-
sion. All patients provided their written informed con-
sent in accordance with the Declaration of Helsinki and
this study was approved by the ethics committee of the
National Cancer Research Institute IRCCS “Giovanni
Paolo II” of Bari, Italy.
BM mononuclear cells (BMMCs) were separated by
Ficoll-Hypaque gradient from 10 ml of heparinized BM
aspirate for each sample. BM stromal cell (BMSCs) were
isolated by plastic adherence of BMMCs on polystyrene
flasks in DMEM medium (Euroclone, Milan, Italy) sup-
plemented with 10% fetal bovine serum (FBS, Sigma, St.
Louis, MO, USA) for about 2 weeks. Fibroblasts were
then purified from BMSCs by immunoselection using
D7-FIB-conjugated (anti-fibroblasts) microbeads (Milte-
nyiBiotec, Italy). Briefly, up to 107 cells were centrifuged
(300Xg) for 10′ and then resuspended in a Phosphate-
Buffered Saline solution (Euroclone, Milan, Italy) added
with 0.5% Bovine Serum Albumin (Sigma, St. Louis,
MO, USA), and 2 mM sEDTA (Sigma, St. Louis, MO,
USA). The cells were incubated at room temperature
(RT) in the presence of Anti-Fibroblast MicroBeads for
30 min, then washed, centrifuged (300Xg) for 10 min
and resuspended in 500 μL of buffer to undergo
immunomagnetic positive separation in autoMACS Pro
Separator (Miltenyi Biotec, Italy), according to manufac-
turer protocols. The proportion of CAF obtained after
separation ranged between 4 × 105 and 1 × 106 cells/
sample. Once isolated, CAF were expanded (until
passage 4) in 10%FBS-added DMEM and stored for sub-
sequent experiments.
U-266 human myeloma cell line was purchased from
ATCC (LGC Standards, UK) and cultured in RPMI-1640
medium (Euroclone, Milan, Italy) supplemented with
10% FCS.
Cell phenotype characterization
CAF were analyzed in whole heparinized BM aspirate
from each patient sample. The cells were treated with
lysing solution to eliminate erythrocytes and incubated
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with a mouse anti-human αSMA-FITC monoclonal
antibody (Abcam, Cambridge, UK) and a rabbit anti-
human FSP-1 antibody (Sigma-Aldrich, St Louis, MN,
USA), an anti-CD45 (Becton Dickinson (San Josè,
CA, USA). Corresponding cell surface antigens were
detected by flow cytometryusing a FACSCanto cyt-
ometer (Becton-Dickinson) with the FACSDiva soft-
ware (Becton-Dickinson) and the negative controls
included isotype-matched antibodies. CAF were
enumerated by quantifying the proportion of α-SMA/
FSP-1 co-expressing cells within the gated CD45-
negative cells, as reported [3].
u-PAR gene silencing
u-PAR expression was inhibited in CAF by the anti-
messenger 18-mer oligodeoxynucleotidephosphodiester
aODN42 (50-CGG CGG GTG ACC CAT GTC-30) and
a degenerated 18-mer ODN (dODN) (ISIS Pharmaceuti-
cals, Carlsbad Research Center, CA, USA) was used as
negative control. Uptake and stability of ODN were en-
hanced by combining ODNs (10 mM/l) with the cationic
liposome solution DOTAP (13 mM/l) (Boehringer
Mannheim, Mannheim, Germany), as described [17].
CAF preparations from each sample were cultured at
10 X 104/plate for 72 h (h) in absence or presence of ei-
ther 10 mM DOTAP-combined aODN or dODN in
DMEM containing 10% heat-inactivated FCS. Based on
ODN half-life in culture, a second addition of 5
mMODNs was performed after 24 h and 48 h in CAF
culture. Cell viability were monitored daily by Trypan
blue staining and non-adherent cells enumerated at each
DOTAP/ODN addition and neither viability impairment
nor detached cells were observed. Real-time reverse
transcriptase polymerase reaction (RT-PCR) was used to
monitor changes in u-PAR expression, which appeared
steady reduced after 3-day exposure to aODN. Thus, at
day 4, cells were collected and used for subsequent analyses.
Proliferation studies
CAF (1 × 105/sample) were plated in T25 flasks and in-
cubated with DMEM plus 10% fetal bovine serum (FBS,
Sigma, St. Louis, MO, USA) for 72 h. Then, they were
detached by EDTA at different time points (24, 48, and
72 h) and counted by a cell counter. Similar experiments
were performed on CAFs in absence or presence of
ODNs, to evaluate whether u-PAR expression affects
their replication activity. Moreover, to investigate the ef-
fect of CAF on MM cell proliferation, U266 cells were
cultured in RPMI medium (8 × 104/well) for 96 h in
presence or absence of CM from sMM CAF either
treated or not with anti-uPAR aODN. At different time
points (24, 48, 72 and 96 h), the cells were resuspended
and counted as described.
Western blotting
U266 cells were incubated for 96 h in CM from sMM
CAF previously treated with DOTAP, aODN or dODN,
and then lysed in a 10 mM Tris-HCl buffer solution.
50 μg of the protein extract was electrophoresed in SDS-
10% polyacrylamide gel and then blotted to a polyvinyli-
dene difluoride membrane (Hybond-C Extra; Amersham
Biosciences) for 3 h at 35 V. The membrane was blocked
with 5% skim milk in 20 mM Tris buffer for 1 h at RT
and then incubated overnight with primary antibodies
against proliferating cell nuclear antigen (PCNA, Cell
Signaling, Beverly, MA, USA) (1:2000) and β-Actin
(1:2000) (SIGMA, St. Louis, MO, USA). After incubation
with horseradish peroxidase-conjugated donkey anti-
mouse IgG (Amersham Bioscience, GE Healthcare
Europe GmbH, Milan, Italy) at 1:5000 dilution for 1 h,
the immune-complexes were detected by the enhanced
chemiluminescence ECL™ detection system (Amersham
Bioscience, GE Healthcare Europe GmbH, Milan, Italy).
Immunofluorescence
CAF were cultured on coverslips in DMEM medium in
absence or presence of ODNs for 72 h, then fixed in 4%
paraformaldehyde (Sigma-Aldrich, Italy), permeabilized
in 0.1% Triton X-100 (Sigma-Aldrich, Italy), washed
twice with PBS, and treated with primary fluorescent
mouse-anti-u-PAR (1:40 dilution, Santa Cruz, CA, USA),
mouse-anti-α-SMA (1:800 dilution; Sigma-Aldrich,
Italy), and mouse-anti-Vimentin (1:800 dilution; Sig-
ma-Aldrich, Italy) antibodies. Anti-mouseCy3–conju-
gated IgG, (1:800 dilution; Sigma-Aldrich, Italy), and
anti-mouse FITC-conjugated IgG (1:800; Sigma-Aldrich,
Italy) were used as secondary antibodies. Nuclei were
stained with DAPI. The cells were observed by a fluores-
cence microscope (Leyca DC-200, Leyca Microsystem
Imaging Solutions Ltd., Cambridge, UK) fitted with a
digital camera.
Real-time reverse-transcriptase polymerase chain reaction
(RT-PCR)
Gene expression profile was assessed from total RNA
extracted from CAF of MGUS and MM patients affected
either treated or not with anti-uPAR aODN, as previ-
ously detailed. Complementary DNA was prepared from
1 μg of total RNA using a GoScript reverse transcription
system (Promega, Italy). The relative quantity of urokin-
ase plasminogen activator (u-PA), u-PA receptor (u-
PAR), urokinase plasminogen inhibitor (PAI-1), MMP2,
α-SMA and Vimentin messenger RNA was measured
using the Applied Biosystems 7500 Fast Real-Time PCR
System and calculated with the comparative Ct method
using 18S ribosomal RNA as the normalization gene.
Amplification was performed with the default PCR set-
ting: 40 cycles of 95 °C for 15 s and of 60 °C for 60″
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using SYBR Green-based detection (GoTaqqPCR Master
Mix; Promega, Italy). The sequences of specific primers
were reported in Table 1.
Invasion assay
Invasion capacity of CAFs was evaluated either in ab-
sence or presence of ODNs, as previously described [17].
Briefly, 8 μm–pore size polycarbonate filters (BD Biosci-
ences, Italy) were coated with Matrigel (BD Biosciences,
Italy) and placed in Boyden chambers. 8 × 103 cells were
plated onto the upper side of the chamber. After 18 h–
incubation at 37 °C, the filters were fixed by methanol
and the cells on the upper surface removed by a cotton
swab. The cells migrated onto the lower side of the filter
were stained by Diff-Quick (Mertz-Dade AG, Dade
International, Milan, Italy) and counted by light micros-
copy (40X magnification). Similarly, the invasion ability
of U266 cells was also evaluated. 1 × 104 cells were
plated onto the upper side of the Boyden chamber in ab-
sence or presence of CM from sMM CAF either treated
or not with ODNs. After 6 h–incubation the number of
cells moved across the filter was assessed. Experiments
were performed in triplicate. Invasion was expressed as
mean ± SD of the number of total cells counted/filter.
Statistical analysis
The differences in the values of parameters among the
groups were examined by ANOVA and Tukey’s Multiple
Comparison Test as post hoc analysis through GraphPad
Prism version 5.00 for Windows (GraphPad Software,
San Diego California USA, www.graphpad.com). Results
of qRT-PCR were expressed as median with range.
p-value <0.05 was considered statistically significant.
Results
Frequency and activation state of CAF vary among MM
progression
As depicted in Fig. 1a, flow cytometry analysis demon-
strated that CD45− cells co-expressing FSP-1 and α-SMA,
as major phenotypic markers of CAF, are significantly
increased in the BM of patients with sMM (75 ± 18%)
compared to MGUS (32 ± 10%), aMM (18 ± 8%), rMM
(15 ± 7%). Of note, transcription of α-SMA, vimentin and
MMP-2 genes was up-regulated in CAF from patients with
more active disease, since their fold-change was signifi-
cantly higher in sMM patients with respect to MGUS,
aMM and rMM (p < 0.0001 in all instances) (Fig. 1b).
These data support the idea that fibroblasts at different
phase of the disease are characterized by diverse grades of
activation. By immunofluorescence, we also observed that
CAF from patients with sMM express αSMA, a major
marker of functional activation, at much more intensity
than MGUS, aMM and rMM, as shown in the representa-
tive panels of Fig. 1c. Consistently, CAF from patients with
active symptomatic disease showed a remarkable prolifera-
tive capacity in vitro. Their absolute number rapidly
increased during a 3-day culture period and, after 72 h, was
approximately two-fold higher than CAF from MGUS,
aMM and rMM, exposed to similar culture conditions
(Fig. 2a). When incubated in a Boyden chamber system,
moreover, CAF showed a peculiar invasion potential, which
was significantly pronounced in CAF from sMM as com-
pared to others. Figure 2b exemplifies this difference, show-
ing the higher number of sMM CAF migrated toward
Matrigel-coated filters.
Expression of the fibrinolytic system components by MM-
associated fibroblasts
We investigated by RT-PCR the transcriptomic profile of
the major members of the fibrinolytic system and inter-
estingly found that CAF from patients at diverse phase
of MM progression also show a differential and peculiar
expression of u-PAR, u-PA, and PAI-1. As can be seen in
Fig. 3a, CAF from active sMM hold the highest tran-
scription level of u-PAR and u-PA, showing a significant
up-regulation of these genes as compared to MGUS,
aMM, and rMM, in which their level was globally low.
Similarly, PAI-1 expression was weak and no significant
difference was appreciable between groups. These data
were in part supported by immunofluorescence experi-
ments exploring the expression of u-PAR at protein
level. Representative UV microscopy images in Fig. 3b
Table 1 Primer sequence and qPCR setting
Gene Forward primer Reverse primer
u-PA 5′-AGTGTCAGCAGCCCCACT-3′ 5′-CCCCCTGAGTCTCCCTGG-3’
u-PAR 5′-GCCCAATCCTGGAGCTTGA-3’ 5′-TCCCCTTGCAGCTGTAACACT-3’
PAI-1 5′-CTCCTGGTTCTGCCCAAGTT-3’ 5′-GAGAGGCTCTTGGTCTGAAAG-3’
MMP-2 5′-AGCACCGCGACAAGAAGTAT-3’ 5′-ATTTGTTGCCCAGGAAAGTG-3’
18S rRNA 5′-CGGCTACCACATCCAAGGAA-3’ 5′-GCTGGAATTACCGCGGCT-3’
α-SMA 5′-CTGTTCCAGCCATCCTTCAT-3’ 5′-CCGTGATCTCCTTCTGCATT-3’
Vimentin 5′-TGTCCAAATCGATGTGGATGTTTC-3’ 5′-TTGTACCATTCTTCTGCCTCCTG-3’
PCR setting: 40 cycles of 95 °C for 15 s and of 60 °C for 60 s using SYBR Green–based detection (GoTaqqPCR Master Mix; Promega)
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depict distinctive patterns of u-PAR exposition, appearing
as green fluorescent spots on membranes of CAF from
different moments of MM progression. A dramatic in-
crease of the u-PAR signal was evident in CAF from sMM
with respect to MGUS and aMM, whose florescence was
comparable to rMM.
u-PAR silencing affects CAF phenotype and function in MM
To explore whether u-PAR contributes to the acquisition
of an activated phenotype by fibrobalsts in MM, we
studied how selective u-PAR silencing influences the
expression of α-SMA, MMP-2, u-PA and PAI-1 in CAF
from MGUS, aMM, sMM and rMM. As shown in Fig. 4a,
a
b
c
Fig. 1 a Flow cytometry analysis of CAF frequency (αSMA/FSP-1 positive cells on gated CD45- population) in patients with MGUS, aMM, rMM and
sMM. Data are reported as mean ± SD from three different experiments performed in triplicate (*p < 0.01). On the right, representative flow
cytometry histograms of FSP-1 positive cells for each study group. b Quantitative PCR analysis of α-SMA, Vimentin and MMP-2 in CAF. Results
were obtained in 3 different experiments performed in triplicate. c Representative immunofluorescence panels of α-SMA (red) and Vimentin (red) in
CAF from MGUSand MM patients at different disease phase (600X magnification)
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Fig. 2 a Proliferation assays of CAF plated at 10 × 104/flask and enumerated after 24, 48 and 72 h of culture. Each value is the mean number of
cells ± SD from three different experiments performed in triplicate. b 6-h Matrigel invasion assay. Invasive CAF were counted in each filter by light
microscopy. Each value is the mean number of cells ± SD of three different experiments performed in triplicate (*p < 0.05)
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Fig. 3 a Quantitative PCR analysis of uPA, uPAR, and PAI-1 in CAF from MGUS and MM patients. Data shown were obtained in 3 different experiments
performed in triplicate. b Representative immunofluorescence panels of u-PAR (green) in CAF (600X magnification)
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the exposure to the antisense aODN resulted in a relevant
decrease of u-PAR expression in all study groups, and par-
ticularly in cells from sMM. All u-PAR-silenced cells,
moreover, showed a consensual down-regulation of α-
SMA, and MMP-2 genes and this effect was significant in
CAF from sMM. U-PA underwent similar down-
modulation, although its decrease in u-PAR-silenced cells
reached no significant values in all CAF preparations.
Immunoflurescence experiments emphasized, almost
in part, these data, since after ODN treatment, α-
SMA signal appeared considerably attenuated in CAF
from sMM, while those from MGUS, aMM and rMM
showed comparable levels of the protein either before
or after inhibition of u-PAR gene expression (Fig. 4b).
Furthermore, proliferation and invasion assays per-
formed before and after u-PAR silencing were aimed
at exploring whether the receptor is implicated in
crucial functions of activated CAF. Figure 5a illus-
trates that u-PAR silencing dramatically impaired the
growth kinetics of CAF from sMM, since after expos-
ure to aODN they underwent a two-fold decrease of
their proliferation over 72 h as compared to controls.
No significant modification of the proliferative behav-
ior was noted in CAF from MGUS, aMM and rMM.
Moreover, while these latter showed no changes in
their Matrigel invasion capability after u-PAR inhib-
ition, CAF from sMM resulted significantly restrained
in their invasive attitude, since the number of u-PAR-
silenced cells migrated toward filters was up to three
fold inferior to the controls (Fig. 5b). These data pro-
vide support to the hypothesis that u-PAR/u-PA
system is critically involved in the invasive function
of CAF during MM progression.
uPAR modulation on CAF affects MM cell proliferation and
invasion potential
In order to investigate whether or not CAF influence
MM cell properties in relation to u-PAR expression, we
carried out both proliferation and invasion assays by
stimulating U-266 cells with medium conditioned by pri-
mary sMM CAF either treated or not with anti-u-PAR
aODN. As shown in Fig. 6a, U-266 cells under the
Fig. 4 a Quantitative PCR analysis of uPA, uPAR, PAI-1, α-SMA and MMP-2 in u-PAR-silenced CAF from MGUS and MM patients. Data were obtained
from 3 different experiments performed in triplicate (p < 0.0001). b Representative panels of immunofluorescence staining of α-SMA (red) in u-PAR-
silenced CAF (600X magnification)
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stimulus of CM from sMM CAF showed higher prolifer-
ation capacity than control even at 48 h and, more
significantly, at 72 h of culture. On the contrary, their
proliferation was dramatically reduced in CM from u-
PAR-silenced CAF, since at 96 h of culture their absolute
number was about 3-fold lower than those incubated in
active CAF CM. Results from Western blot analysis sup-
ported these data since the protein expression of the
proliferating cell nuclear antigen (PCNA) in U266 cells
paralleled their proliferation behavior after 96 h of
incubation.
Moreover, as depicted in Fig. 6b, MM cells displayed a
considerable inherited attitude to invade and migrate
toward porous Matrigel-coated filters in vitro and this
property was significantly improved by incubating the
cells in CM from sMM CAF. Notably, when the invasion
experiments were performed using the CM from uPAR-
silenced CAF, the number of U266 cells migrated on the
bottom side of the Boyden chamber was about 2-fold
and more than 3-fold lower than those cultured in nor-
mal medium and in CM from sMM CAF, respectively.
Discussion
The present study focuses on the role of CAF in the
biology of MM progression and emphasizes the contri-
bution of the u-PAR-driven fibrinolytic system to the
process of MM cell expansion within the BM.
It is well accepted that chronic interactions between
malignant PCs and surrounding cells sustain a progres-
sive expansion of the tumor clone within the BM,
Fig. 5 a Proliferation and (b) invasion assays of u-PAR-silenced CAF from patients with MGUS, aMM, rMM and sMM (p < 0.01). Representative optical
microscopy images of Matrigel-invasive CAF are shown in the lower side of the figure
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driving the clinical transition from MGUS to overt MM.
Bone degradation/invasion represents a crucial step of
this process and is mainly ascribed to the enhanced
capacity of tumor cells to produce digestive enzymes as
MMPs and other pro-invasive molecules, disrupt ECM
proteins, and respond to a number of chemotactic stim-
uli by both inflammatory and stromal cells within the
BM [5]. On the other hand, adhesion to ECM proteins
such as fibronectin and laminin, and stromal elements
as osteoblasts, endothelial cells and particularly fibro-
blasts, prompt myeloma cell survival and drug resistance
[18], further promoting the disease progression. In this
scenario, a fraction of BM fibroblasts, known as CAF
keeping a chronic state of functional activation is
thought to actively support tumor progression [3].
Our data are in line with these observations, since
CD45−/α-SMA+/FSP-1+ cells showing a typical CAF
phenotype more largely infiltrate BM of patients with ac-
tive MM than MGUS, aMM and rMM, suggesting that
CAF expansion parallels MM growth. Consistently, gene
expression and immunofluorescence analyses indicated
that CAF in symptomatic MM patients express signifi-
cant higher levels of structural proteins as α-SMA and
vimentin, recognized as fibroblast activation markers,
and the metalloproteinase MMP-2. The condition of
prominent activation also impacts the invasive and pro-
liferative ability of fibroblasts, which are much more
pronounced in the sMM compared to the other stages
of the disease. These observations emphasizing the hy-
pothesis that CAF in MM, as in other solid neoplasm,
derive from enhanced commitment of normal fibroblasts
to more activated myofibroblasts with improved ECM-
degrading potential [19]. At this regard, recent studies
reported that MM cell interaction with tumor stroma re-
sults in a critical increase of u-PA and other ECM pro-
tein levels, stressing the role of the fibrinolytic system in
the MM-associated bone destruction and progression
[20, 21]. Moreover, binding of u-PA to its receptor
strongly accelerates the enzymatic activity of u-PA itself
and also described to promote angiogenesis [22, 23].
Our findings intriguingly indicated that, as compared to
MGUS, aMM and MM in remission phase, CAF from
sMM significantly overexpress both u-PA and u-PAR
genes as key components of the fibrinolytic system, and
display higher level of u-PAR on cell surface. This may
be ascribed to the increased BM concentrations reached
Fig. 6 a Proliferation assay of U266 myeloma cells enumerated at 24, 48, 72, and 96 h of culture in normal medium (CTR) or in conditioned medium
(CM) from sMM untreated, DOTAP-, aODN-, and dODN-treated CAF. Western blot image shows the expression of the proliferation cell nuclear antigen
(PCNA) in U266 cells at 96 h of incubation in the above conditions. b Graph depicting the quantification of U266 cells migrated under the stimulus of
normal medium (CTR) or medium conditioned by sMM untreated, DOTAP-, aODN-, and dODN-treated CAF (*p < 0.05). Representative optical microscopy
images for each culture condition of the invasion assay
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in active MM by a number of inflammatory factors pro-
duced by stromal, immune and tumor cells themselves
as effect of multiple reciprocal paracrine and cell-to-cell
interactions. Some of these, such as TGF-β and SDF-1,
are indeed reported to mediate the up-regulation of the
u-PA/u-PAR axis [6, 24] as well as the switch of CAF to
a strongly activated phenotype [3].
In parallel with a strongly activated phenotype, BM-
infiltrating CAF in active MM rather than MGUS,
asymptomatic and treated patients, show a peculiar pro-
invasive asset, which also support bone matrix degrad-
ation and plasma cell invasion. The idea that activation
of the u-PA/u-PAR system is connected to the global
triggering of CAF function in active MM is further sug-
gested by results from our u-PAR silencing experiments.
In fact, inhibition of u-PAR mRNA by selective anti-
sense oligonucleotides produced a consensual down-
regulation of u-PA and MMP-2 expression as well as of
α-SMA, at both mRNA and protein level, and this effect
was particularly evident in active MM as compared to
other clinical phases of the disease. It is thus conceivable
that, as the disease progresses, structural and functional
changes in BM fibroblasts also involve, and are intercon-
nected with, modulation of the u-PA/u-PAR axis compo-
nents, although further research is needed to identify
specific mechanisms of reciprocal intracellular signal
control. At functional level, we observed that more in-
tense proliferative and invasion attitude characterizes
CAF expressing higher levels of u-PAR as those from ac-
tive symptomatic MM and, notably, these properties
were dramatically restrained by u-PAR silencing. Finally,
in our in vitro experiments CAF showed to affect MM
cell functions by a paracrine mechanism since malignant
cells significantly increased their replication and invasion
ability under the stimulus of CM from sMM CAF, while
this effect was dramatically lowered by incubation in
CM from u-PAR-silenced CAF. Although further investi-
gation is needed to better characterize the role of u-PA/
uPAR system in MM, our findings provide insights
about it as a critical part of the complex network of
paracrine and physical signals implicated in the biology
of MM progression.
Conclusions
To the best of our knowledge, this is the first report in
which the molecular role of u-PAR/u-PA system
emerges as directly implicated in the biology of CAF and
interconnected with the pathophysiology of MM pro-
gression. Based on these and indirect evidences from
others, u-PAR may be recognized as an additional
marker of CAF activation in MM and a key molecular
player of their capability to promote bone matrix de-
struction and ECM degradation, thus favoring migration
and invasive properties of malignant plasma cells. In this
view, the use of novel anti-u-PAR compounds, including
antagonist peptides and monoclonal antibodies as well
as emerging gene-silencing approaches [25], acquires a
robust rationale in MM and might be effective in target-
ing, at the same time, both malignant cells and tumor
microenvironment.
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